Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature.
Angiomyolipoma
Anticonvulsant
Costs
Epilepsy
Genetics
MTOR inhibitor
Seizure
Sociodemographic characteristics
Subependymal giant cell astrocytoma
TSC
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 06 2021
02 06 2021
Historique:
received:
19
12
2020
accepted:
22
04
2021
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Tuberous sclerosis complex (TSC) is a monogenetic, multisystem disorder characterized by benign growths due to TSC1 or TSC2 mutations. This German multicenter study estimated the costs and related cost drivers associated with organ manifestations in adults with TSC. A validated, three-month, retrospective questionnaire assessed the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket (OOP), and nursing care-level costs among adult individuals with TSC throughout Germany from a societal perspective (costing year: 2019). We enrolled 192 adults with TSC (mean age: 33.4 ± 12.7 years; range: 18-78 years, 51.6% [n = 99] women). Reported TSC disease manifestations included skin (94.8%) and kidney and urinary tract (74%) disorders, epilepsy (72.9%), structural brain defects (67.2%), psychiatric disorders (50.5%), heart and circulatory system disorders (50.5%), and lymphangioleiomyomatosis (11.5%). TSC1 and TSC2 mutations were reported in 16.7% and 25% of respondents, respectively. Mean direct health care costs totaled EUR 6452 (median EUR 1920; 95% confidence interval [CI] EUR 5533-7422) per patient over three months. Medication costs represented the major direct cost category (77% of total direct costs; mean EUR 4953), and mechanistic target of rapamycin (mTOR) inhibitors represented the largest share (68%, EUR 4358). Mean antiseizure drug (ASD) costs were only EUR 415 (6%). Inpatient costs (8%, EUR 518) and outpatient treatment costs (7%; EUR 467) were important further direct cost components. The mean care grade allowance as an approximator of informal nursing care costs was EUR 929 (median EUR 0; 95% CI EUR 780-1083) over three months. Mean indirect costs totaled EUR 3174 (median EUR 0; 95% CI EUR 2503-3840) among working-age individuals (< 67 years in Germany). Multiple regression analyses revealed mTOR inhibitor use and persistent seizures as independent cost-driving factors for total direct costs. Older age and disability were independent cost-driving factors for total indirect costs, whereas epilepsy, psychiatric disease, and disability were independent cost-driving factors for nursing care costs. This three-month study revealed substantial direct healthcare, indirect healthcare, and medication costs associated with TSC in Germany. This study highlights the spectrum of organ manifestations and their associated treatment needs in the German healthcare setting. DRKS, DRKS00016045. Registered 01 March 2019, http://www.drks.de/DRKS00016045 .
Sections du résumé
BACKGROUND
Tuberous sclerosis complex (TSC) is a monogenetic, multisystem disorder characterized by benign growths due to TSC1 or TSC2 mutations. This German multicenter study estimated the costs and related cost drivers associated with organ manifestations in adults with TSC.
METHODS
A validated, three-month, retrospective questionnaire assessed the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket (OOP), and nursing care-level costs among adult individuals with TSC throughout Germany from a societal perspective (costing year: 2019).
RESULTS
We enrolled 192 adults with TSC (mean age: 33.4 ± 12.7 years; range: 18-78 years, 51.6% [n = 99] women). Reported TSC disease manifestations included skin (94.8%) and kidney and urinary tract (74%) disorders, epilepsy (72.9%), structural brain defects (67.2%), psychiatric disorders (50.5%), heart and circulatory system disorders (50.5%), and lymphangioleiomyomatosis (11.5%). TSC1 and TSC2 mutations were reported in 16.7% and 25% of respondents, respectively. Mean direct health care costs totaled EUR 6452 (median EUR 1920; 95% confidence interval [CI] EUR 5533-7422) per patient over three months. Medication costs represented the major direct cost category (77% of total direct costs; mean EUR 4953), and mechanistic target of rapamycin (mTOR) inhibitors represented the largest share (68%, EUR 4358). Mean antiseizure drug (ASD) costs were only EUR 415 (6%). Inpatient costs (8%, EUR 518) and outpatient treatment costs (7%; EUR 467) were important further direct cost components. The mean care grade allowance as an approximator of informal nursing care costs was EUR 929 (median EUR 0; 95% CI EUR 780-1083) over three months. Mean indirect costs totaled EUR 3174 (median EUR 0; 95% CI EUR 2503-3840) among working-age individuals (< 67 years in Germany). Multiple regression analyses revealed mTOR inhibitor use and persistent seizures as independent cost-driving factors for total direct costs. Older age and disability were independent cost-driving factors for total indirect costs, whereas epilepsy, psychiatric disease, and disability were independent cost-driving factors for nursing care costs.
CONCLUSIONS
This three-month study revealed substantial direct healthcare, indirect healthcare, and medication costs associated with TSC in Germany. This study highlights the spectrum of organ manifestations and their associated treatment needs in the German healthcare setting.
TRIAL REGISTRATION
DRKS, DRKS00016045. Registered 01 March 2019, http://www.drks.de/DRKS00016045 .
Identifiants
pubmed: 34078440
doi: 10.1186/s13023-021-01838-w
pii: 10.1186/s13023-021-01838-w
pmc: PMC8170458
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
250Références
BMJ Open. 2017 Oct 5;7(10):e015236
pubmed: 28982809
Orphanet J Rare Dis. 2018 Jul 17;13(1):117
pubmed: 30016967
Front Neurol. 2017 Dec 22;8:712
pubmed: 29312132
Front Neurol. 2020 Sep 16;11:972
pubmed: 33041968
Value Health. 2008 Jul-Aug;11(4):539-44
pubmed: 18194408
Orphanet J Rare Dis. 2019 Feb 7;14(1):31
pubmed: 30732630
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Orphanet J Rare Dis. 2020 Sep 25;15(1):264
pubmed: 32988393
Epilepsy Behav. 2020 Nov;112:107494
pubmed: 33181900
Nat Rev Dis Primers. 2016 May 26;2:16035
pubmed: 27226234
Neuroepidemiology. 2009;33(4):335-41
pubmed: 19887839
J Health Econ. 1995 Jun;14(2):171-89
pubmed: 10154656
Epilepsy Res. 1999 Jan;33(1):39-55
pubmed: 10022365
J Child Neurol. 2015 Apr;30(5):563-9
pubmed: 24667738
J Med Econ. 2018 Oct;21(10):953-959
pubmed: 29890870
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Epilepsia. 2010 Jul;51(7):1236-41
pubmed: 20041940
Expert Rev Clin Pharmacol. 2021 May 31;:1-12
pubmed: 33792454
J Med Econ. 2015;18(12):1060-70
pubmed: 26201433
Orphanet J Rare Dis. 2016 May 04;11(1):58
pubmed: 27145956
Epilepsia. 2015 Apr;56(4):e36-9
pubmed: 25778844
Appl Health Econ Health Policy. 2019 Oct;17(5):707-722
pubmed: 31161366
Stat Med. 2000 Dec 15;19(23):3219-36
pubmed: 11113956
Orphanet J Rare Dis. 2014 Dec 18;9:210
pubmed: 25519771
Orphanet J Rare Dis. 2018 Oct 25;13(1):186
pubmed: 30359266
Epilepsia. 2015 Sep;56(9):1388-97
pubmed: 26235849
Epilepsia. 2021 Apr;62(4):831-845
pubmed: 33656182
Pediatr Neurol. 2013 Oct;49(4):243-54
pubmed: 24053982
Lancet Neurol. 2015 Jul;14(7):733-45
pubmed: 26067126
Pharmacoeconomics. 1998 May;13(5 Pt 1):487-97
pubmed: 10180748
Front Neurol. 2020 Aug 28;11:904
pubmed: 32982929
Genet Mol Biol. 2017 Jan-Mar;40(1):69-79
pubmed: 28222202
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
Epilepsia. 2019 Aug;60(8):1697-1710
pubmed: 31247127
Epilepsy Behav. 2021 Feb;115:107647
pubmed: 33358132
J Med Econ. 2015 May;18(5):349-56
pubmed: 25525770
Pharmacoeconomics. 2008;26(6):463-76
pubmed: 18489198
World Neurosurg. 2016 Jul;91:97-105
pubmed: 27025453
Arch Neurol. 1991 Apr;48(4):400-1
pubmed: 2012513
J Med Econ. 2016 Dec;19(12):1116-1126
pubmed: 27310569
Eur J Hum Genet. 2005 Jun;13(6):731-41
pubmed: 15798777
J Med Econ. 2017 Apr;20(4):388-394
pubmed: 27998195
Chest. 2015 Aug;148(2):444-449
pubmed: 25789699
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
Lancet. 1998 May 16;351(9114):1490
pubmed: 9605811
Epilepsy Res. 1990 May-Jun;6(1):66-81
pubmed: 2357957
Epilepsy Behav. 2012 Apr;23(4):451-7
pubmed: 22381385
Handb Clin Neurol. 2013;111:627-33
pubmed: 23622210
Orphanet J Rare Dis. 2020 Jan 21;15(1):23
pubmed: 31964424
Mol Med Rep. 2013 Sep;8(3):909-13
pubmed: 23846400
Epilepsy Behav. 2018 Jun;83:28-35
pubmed: 29649671
JAMA Neurol. 2021 Mar 1;78(3):285-292
pubmed: 33346789
Br J Dermatol. 2016 Jun;174(6):1282-9
pubmed: 26800857
Epilepsy Behav. 2019 Feb;91:94-98
pubmed: 29941212
Eur J Paediatr Neurol. 2019 May;23(3):392-403
pubmed: 30871879
J Med Econ. 2016 Nov;19(11):1087-1098
pubmed: 27267148